BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeline of innovative therapies and a pipeline of biosimilars, today announcedthat Jin-Chen Yu, SVP, Research willpresent a talk on BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Sele...
Guangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeline of innovative therapies and a pipeline of biosimilars, today announcedthe company will present two posters at the 2022 San Antonio Breast CancerSymposium (SABCS) taking place De...
Guangzhou, China --(BUSINESSWIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase III clinical studyfor BAT2306, a proposed biosimilar of Cosentyx® (secukinumab). The clinical study is a randomized,double-blind, para...